The Sackler Institute for Nutrition Science at the New York Academy of Sciences, in collaboration with the World Health Organization, has developed an unprecedented global research agenda for the nutrition science community, policy makers, and global leaders. Developed through research and insights from more than 300 experts in nutrition science and public health, the agenda identifies critical research and knowledge gaps that hamper the development of effective, evidence-based interventions to tackle malnutrition.
Experts will present and discuss this agenda and explore how to effectively translate the findings into action and help improve human nutrition worldwide.
WHEN:8:30 a.m., Monday, December 17 (Keynote address will take place Monday. The conference will continue throughout the day on Tuesday, December 18.)
WHERE: The New York Academy of Sciences Conference Center
7 World Trade Center, 250 Greenwich Street, 40th Floor, New York, NY 10007
WHO: Interview and photo opportunities will be available at the forum with:
-
Francesco Branca, MD, PhD, The World Health Organization
-
Mandana Arabi, MD, PhD, The Sackler Institute for Nutrition Science
-
Additional speakers include representatives from China, Malaysia, South Africa, Qatar, Canada, the Netherlands, and more
WHY: The global crisis of malnutrition affects two billion of the world's seven billion people. Its effects are devastating and extend far beyond health outcomes: malnutrition on a global scale can affect workforce capacity, threaten political stability, and disrupt economic progress. However, a lack of knowledge persists about the complex factors contributing to this global problem and the most effective ways to address it. To achieve real impact, research gaps must be identified and addressed before effective interventions can be developed at the national and local levels. A focused and science-based approach can help activate critical research and spur public policy changes to tackle malnutrition in developed and developing nations.
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy